Table 2.
Association between colorectal cancer-related screening and other cancer screening tests among men.
| Cancer screening test | All men |
European–American |
African–American |
|||
|---|---|---|---|---|---|---|
| Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) | |
| Ever participating in any CRC screen test | ||||||
|
| ||||||
| Any cancer test | 2.62 (1.64–4.19) | 1.63 (0.98–2.74) | 2.71 (1.61–4.55) | 1.77 (0.99–3.14) | 2.26 (0.76–6.75) | 1.44 (0.41–5.06) |
|
| ||||||
| PSA | 1.95 (1.14–3.32) | 1.39 (0.78–2.48) | 2.17 (1.19–3.97) | 1.62 (0.84–3.19) | 1.20 (0.38–3.98) | 0.85 (0.23–3.19) |
|
| ||||||
| DRE | 3.20 (1.97–5.20) | 2.06 (1.21–3.51) | 3.28 (1.92–5.61) | 2.13 (1.18–3.85) | 2.82 (0.87–9.16) | 1.90 (0.52–7.02) |
|
| ||||||
| Adherence to colonoscopy | ||||||
|
| ||||||
| Any cancer test | 2.76 (1.85–4.12) | 1.71 (1.08–2.72) | 2.54 (1.63–3.97) | 1.44 (0.85–2.44) | 3.67 (1.44–9.36) | 3.36 (1.04–10.17) |
|
| ||||||
| PSA | 2.43 (1.57–3.75) | 1.87 (1.14–3.07) | 2.55 (1.56–4.15) | 1.87 (1.07–3.80) | 2.00 (0.75–5.35) | 1.42 (0.44–4.52) |
|
| ||||||
| DRE | 2.74 (1.83–4.10) | 1.79 (1.19–2.87) | 2.65 (1.70–4.14) | 1.60 (0.94–2.73) | 2.90 (1.12–7.51) | 3.21 (0.96–10.75) |
|
| ||||||
| Adherence to flexible sigmoidoscopy | ||||||
|
| ||||||
| Any cancer test | 0.97 (0.57–1.64) | 1.04 (0.61–1.77) | 0.75 (0.41–1.39) | 0.75 (0.40–1.38) | 2.33 (0.79–6.86) | 2.17 (0.72–6.56) |
|
| ||||||
| PSA | 1.14 (0.67–1.96) | 1.22 (0.70–2.10) | 1.06 (0.56–2.00) | 1.06 (0.56–2.00) | 1.53 (0.53–4.42) | 1.38 (0.47–4.08) |
|
| ||||||
| DRE | 0.90 (0.53–1.54) | 0.98 (0.57–1.68) | 0.81 (0.43–1.53) | 0.81 (0.43–1.52) | 1.48 (0.52–4.26) | 1.41 (0.48–4.15) |
|
| ||||||
| Adherence to fecal occult blood test | ||||||
|
| ||||||
| Any cancer test | 1.48 (0.69–3.15) | 1.59 (0.71–3.55) | 1.77 (0.73–4.25) | 1.82 (0.73–4.54) | 0.74 (0.14–3.91) | – |
|
| ||||||
| PSA | 1.99 (0.99–4.03) | 1.89 (0.91–3.91) | 1.96 (0.90–4.24) | 1.85 (0.83–4.11) | 2.18 (0.41–11.68) | – |
|
| ||||||
| DRE | 2.00 (0.91–4.41) | 2.20 (0.95–5.10) | 2.11 (0.87–5.11) | 2.23 (0.88–5.61) | 1.50 (0.24–9.55) | – |
|
| ||||||
| Adherence to any CRC screening test | ||||||
|
| ||||||
| Any cancer test | 2.59 (1.72–3.90) | 1.68 (1.05–2.66) | 2.37 (1.50–3.74) | 1.52 (0.90–2.57) | 3.48 (1.35–8.97) | 2.85 (0.88–9.20) |
|
| ||||||
| PSA | 2.58 (1.62–4.11) | 2.05 (1.23–3.41) | 2.66 (1.58–4.49) | 2.07 (1.17–3.67) | 2.29 (0.82–6.41) | 1.79 (0.50–6.41) |
|
| ||||||
| DRE | 2.75 (1.82–4.17) | 1.94 (1.20–3.13) | 2.65 (1.67–4.20) | 1.87 (1.10–3.18) | 3.02 (1.14–8.02) | 2.72 (0.79–9.39) |
Any CRC screening adjusted forage, plan on colonoscopy in next 10 years, health insurance, urban vs rural status and CRC awareness and attitude scores. Adherence to colonoscopy adjusted forage, plan on colonoscopy in next 10 years, know someone with CRC, employment status, income, urban vs rural status and CRC awareness and attitude scores. Ad herence to flexible sigmoidoscopy adjusted for age and urban vs rural status. Adherence to fecal occult blood test adjusted forage, concern for CRC development, transportation means to clinic and urban vs rural status. Adherence to any CRC screening test adjusted forage, plan on colonoscopy in next 10 years, know someone with CRC, urban vs rural status, and CRC awareness, knowledge and attitude scores.
–: Validity of model fit was questionable due to limited sample sizes. Anycancertest refers to any prostate cancer test (i.e., DRE or PSA); CRC: Colorectal cancer; DRE: Digital rectal examination; OR: Odds ratio; PSA: Prostate-specific antigen.